SI2176430T1 - Napovedni marker za zdravljenje z inhibitorjem EGFR - Google Patents
Napovedni marker za zdravljenje z inhibitorjem EGFRInfo
- Publication number
- SI2176430T1 SI2176430T1 SI200830833T SI200830833T SI2176430T1 SI 2176430 T1 SI2176430 T1 SI 2176430T1 SI 200830833 T SI200830833 T SI 200830833T SI 200830833 T SI200830833 T SI 200830833T SI 2176430 T1 SI2176430 T1 SI 2176430T1
- Authority
- SI
- Slovenia
- Prior art keywords
- egfr inhibitor
- inhibitor treatment
- predictive marker
- predictive
- marker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114302 | 2007-08-14 | ||
PCT/EP2008/006523 WO2009021684A2 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treatment |
EP20080785429 EP2176430B9 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2176430T1 true SI2176430T1 (sl) | 2013-01-31 |
Family
ID=40227562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200830833T SI2176430T1 (sl) | 2007-08-14 | 2008-08-07 | Napovedni marker za zdravljenje z inhibitorjem EGFR |
Country Status (14)
Country | Link |
---|---|
US (2) | US20110184005A1 (sl) |
EP (1) | EP2176430B9 (sl) |
JP (1) | JP5368445B2 (sl) |
KR (1) | KR101169246B1 (sl) |
CN (1) | CN101827947B (sl) |
AU (1) | AU2008286337B2 (sl) |
CA (1) | CA2695473C (sl) |
DK (1) | DK2176430T5 (sl) |
ES (1) | ES2395881T3 (sl) |
IL (1) | IL203647A (sl) |
MX (1) | MX2010001583A (sl) |
PL (1) | PL2176430T3 (sl) |
SI (1) | SI2176430T1 (sl) |
WO (1) | WO2009021684A2 (sl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2969174B1 (fr) | 2010-12-16 | 2014-03-14 | Commissariat Energie Atomique | Ligand specifique de la proteine lar |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5525464A (en) * | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5795716A (en) * | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
AU2004211955B2 (en) * | 2003-02-06 | 2009-05-14 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
EP2226396A1 (en) * | 2003-05-30 | 2010-09-08 | Genomic Health, Inc. | Gene expression markers for response to EGFR inhibitor drugs |
GB0312451D0 (en) * | 2003-05-30 | 2003-07-09 | Astrazeneca Uk Ltd | Process |
NZ543234A (en) * | 2003-05-30 | 2009-04-30 | Astrazeneca Uk Ltd | Marker genes and uses thereof to identify cancer patients that will respond to erbb tyrosine kinase inhibitors |
US20060234237A1 (en) * | 2004-01-08 | 2006-10-19 | Amler Lukas C | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
-
2008
- 2008-08-07 ES ES08785429T patent/ES2395881T3/es active Active
- 2008-08-07 WO PCT/EP2008/006523 patent/WO2009021684A2/en active Application Filing
- 2008-08-07 PL PL08785429T patent/PL2176430T3/pl unknown
- 2008-08-07 US US12/672,959 patent/US20110184005A1/en not_active Abandoned
- 2008-08-07 CN CN2008801027038A patent/CN101827947B/zh active Active
- 2008-08-07 CA CA 2695473 patent/CA2695473C/en active Active
- 2008-08-07 KR KR20107003253A patent/KR101169246B1/ko active IP Right Grant
- 2008-08-07 JP JP2010520472A patent/JP5368445B2/ja active Active
- 2008-08-07 AU AU2008286337A patent/AU2008286337B2/en active Active
- 2008-08-07 MX MX2010001583A patent/MX2010001583A/es active IP Right Grant
- 2008-08-07 DK DK08785429T patent/DK2176430T5/da active
- 2008-08-07 SI SI200830833T patent/SI2176430T1/sl unknown
- 2008-08-07 EP EP20080785429 patent/EP2176430B9/en active Active
-
2010
- 2010-02-01 IL IL203647A patent/IL203647A/en active IP Right Grant
-
2013
- 2013-04-01 US US13/854,180 patent/US9121067B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2395881T9 (es) | 2013-09-06 |
DK2176430T5 (da) | 2013-09-08 |
KR101169246B1 (ko) | 2012-08-03 |
CA2695473A1 (en) | 2009-02-19 |
US9121067B2 (en) | 2015-09-01 |
IL203647A (en) | 2013-02-28 |
AU2008286337B2 (en) | 2011-10-27 |
US20110184005A1 (en) | 2011-07-28 |
CA2695473C (en) | 2013-10-01 |
DK2176430T3 (da) | 2012-10-08 |
CN101827947A (zh) | 2010-09-08 |
PL2176430T3 (pl) | 2013-02-28 |
EP2176430A2 (en) | 2010-04-21 |
WO2009021684A2 (en) | 2009-02-19 |
BRPI0815543A2 (pt) | 2013-03-12 |
US20130210843A1 (en) | 2013-08-15 |
JP2010535524A (ja) | 2010-11-25 |
EP2176430B1 (en) | 2012-09-19 |
KR20100037634A (ko) | 2010-04-09 |
ES2395881T3 (es) | 2013-02-15 |
WO2009021684A3 (en) | 2009-04-16 |
MX2010001583A (es) | 2010-03-15 |
EP2176430B9 (en) | 2013-07-24 |
AU2008286337A1 (en) | 2009-02-19 |
CN101827947B (zh) | 2013-11-13 |
JP5368445B2 (ja) | 2013-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257418A (en) | Methods for treating addiction | |
IL200779A0 (en) | Pdgfr beta-specific inhibitors | |
HK1176601A1 (zh) | 抑制劑 | |
HK1142796A1 (en) | Surgical kits | |
EP2229363A4 (en) | Renin Inhibitors | |
HK1203305A1 (en) | Methods for treating psoriasis | |
BRPI0815415A2 (pt) | Marcador preditivo para tratamento inibidor de egfr | |
EP2177529A4 (en) | NEW DE-SECRETASE INHIBITOR | |
EP2222662A4 (en) | INHIBITORS OF KYNURENINE AMINO TRANSFERASE | |
IL203594A (en) | Predictive marker for treatment of egfr inhibitor | |
BRPI0815545A2 (pt) | Marcadores preditivos para o tratamento com inibidores de egfr | |
IL196807A0 (en) | Inhibitors for glyt-1 | |
IL203599A (en) | Mark @ for treatment @ inhibitor @ of @ egfr | |
GB0809689D0 (en) | Markers for prostate cancee | |
BRPI0814354A2 (pt) | Marcador preditivo para tratamento com inibidor de egfr | |
SI2176430T1 (sl) | Napovedni marker za zdravljenje z inhibitorjem EGFR | |
EP2190811A4 (en) | INHIBITORS OF THE RENIN | |
EP2188256A4 (en) | INHIBITORS OF THE RENIN | |
BRPI0817361A2 (pt) | Marcador preditivo para tratamento com inibidor de egfr | |
BRPI0815546A2 (pt) | Marcador preditivo para tratamento com inibidor da egfr | |
GB0714941D0 (en) | Inhibitors | |
BRPI0815372A2 (pt) | marcador preditivo para o tratamento com inibidor do egfr | |
GB0720364D0 (en) | Inhibitor | |
GB0713152D0 (en) | Phosphodlesterase inhibitors | |
GB0707499D0 (en) | Novel inhibitors |